Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective study on the prevention of Neratinib-related diarrhea in a Chinese
population, exploring the best options for reducing the incidence of neratinib-related
diarrhea through either pharmacologic intervention (prophylactic antidiarrheal therapy) or
non-pharmacologic intervention (dose escalation program).